2025
Behavioral Therapy as an Adjunct to Buprenorphine Treatment for Opioid Use Disorder
McHugh R, Bailey A, McConaghy B, Weiss R, Fiellin D, Hillhouse M, Moore B, Fitzmaurice G. Behavioral Therapy as an Adjunct to Buprenorphine Treatment for Opioid Use Disorder. JAMA Network Open 2025, 8: e2528529. PMID: 40833692, PMCID: PMC12368672, DOI: 10.1001/jamanetworkopen.2025.28529.Peer-Reviewed Original ResearchDiagnostic and Statistical ManualBehavioral therapyCognitive behavioral therapyOpioid use disorderUse disorderBuprenorphine treatmentContingency managementDiagnostic and Statistical Manual of Mental DisordersStatistical manual of mental disordersManual of mental disordersBuprenorphine treatment of opioid use disorderAddiction Severity IndexRates of treatment responseTreatment of opioid use disorderBuprenorphine retentionRandomized clinical trialsEffects of subgroupsBehavioral treatmentMental disordersOpioid dependenceSecondary analysisMedical managementClinical trialsCourse of treatmentModerating effectCharacteristics of Veterans Receiving Medication for Opioid Use Disorder: An Observational Cohort Study
Jones K, Mandavia A, Gurewich D, Wyse J, Sung M, Becker W, Livingston N. Characteristics of Veterans Receiving Medication for Opioid Use Disorder: An Observational Cohort Study. Journal Of General Internal Medicine 2025, 1-4. PMID: 40588710, DOI: 10.1007/s11606-025-09657-6.Peer-Reviewed Original ResearchHealth Services Usage in Patients Receiving Buprenorphine for Opioid Use Disorder or Long-Term Opioid Therapy for Chronic Pain: Retrospective Cohort Study
Savitz S, Stevens M, Nath B, D'Onofrio G, Melnick E, Jeffery M. Health Services Usage in Patients Receiving Buprenorphine for Opioid Use Disorder or Long-Term Opioid Therapy for Chronic Pain: Retrospective Cohort Study. JMIR Formative Research 2025, 9: e66596. PMID: 40537088, DOI: 10.2196/66596.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosLong-term opioid therapyIn-person careMental illness cohortOpioid use disorderIn-personTelemedicine visitsChronic painPain medicineOpioid therapyEmergency medicineMental healthFamily practiceHealth service usageChronic opioidsPercentage of visitsIn-Person VisitsIn-person treatmentPoor outcomeAdministrative claims dataUse disorderMedicare Advantage patientsOptumLabs Data WarehouseVulnerable patient populationCare deliveryCognitive bias modification for individuals with opioid use disorder and chronic pain did not predict changes in clinical outcomes.
Wolkowicz N, Pittman B, Schrader S, Wesolowicz D, Sofuoglu M, Heapy A, MacLean R. Cognitive bias modification for individuals with opioid use disorder and chronic pain did not predict changes in clinical outcomes. Journal Of Studies On Alcohol And Drugs 2025 PMID: 40536409, DOI: 10.15288/jsad.25-00057.Peer-Reviewed Original ResearchCognitive bias modificationAttentional biasOpioid cravingBias modificationCBM effectsSubstance use disordersPain severityChronic painClinical outcomesAddiction severityOpioid use disorderUse disorderNaturalistic settingsNeutral-cueOpioid withdrawalPain cuesCravingDiverse sampleSalient outcomesSubstance typePreliminary effectivenessPrimary clinical outcomePain catastrophizingModerate painPain intensityA Review of Relapse in Opioid Use Disorder
Draghmeh K, Gold M, Fuehrlein B. A Review of Relapse in Opioid Use Disorder. Current Addiction Reports 2025, 12: 58. DOI: 10.1007/s40429-025-00672-5.Peer-Reviewed Original ResearchUse disorderEnhance treatment retentionMindfulness-based therapyStress system dysregulationRelapse vulnerabilityOpioid use disorderNeurobiological mechanismsDopamine deficitMedication-Assisted TreatmentContingency managementTreatment retentionPsychosocial interventionsMechanisms of relapseReduce relapseBehavioral componentsReviewOpioid use disorderSignificant public health challengeSystem dysregulationPublic health challengeRelapse rateAt-risk populationsSocietal burdenEmergency therapyAt-riskRelapseInformation Needs for Opioid Use Disorder Treatment Using Buprenorphine Product: Qualitative Analysis of Suboxone-Focused Reddit Data
Basak M, Sharif O, Lord S, Borodovsky J, Marsch L, Springer S, Nunes E, Brackett C, Archibald L, Preum S. Information Needs for Opioid Use Disorder Treatment Using Buprenorphine Product: Qualitative Analysis of Suboxone-Focused Reddit Data. Journal Of Medical Internet Research 2025, 27: e68886. PMID: 40489766, PMCID: PMC12186000, DOI: 10.2196/68886.Peer-Reviewed Original ResearchConceptsLarge-scale dataPotential rumorsSocial media platformsReddit postsInformation needsOpioid use disorder treatmentOpioid use disorderMedia platformsUse disorderDisorder treatmentRedditSocial mediaHypothesis generationInformationFood and Drug Administration-approved medicationsClinical expertsFrequent topicTreatment informationSubstance useCannabis Legalization and Opioid Use Disorder in Veterans Health Administration Patients
Mannes Z, Wall M, Alschuler D, Malte C, Olfson M, Livne O, Fink D, Keyhani S, Keyes K, Martins S, Cerdá M, Sacco D, Gutkind S, Maynard C, Sherman S, Saxon A, Hasin D. Cannabis Legalization and Opioid Use Disorder in Veterans Health Administration Patients. JAMA Health Forum 2025, 6: e251369. PMID: 40512510, PMCID: PMC12166489, DOI: 10.1001/jamahealthforum.2025.1369.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationVeterans Health Administration patientsMedical cannabis lawsOpioid use disorderPrevalence of opioid use disorderClassification of diseasesRecreational cannabis lawsChronic painVeterans Health Administration electronic health recordClinical ModificationConsistent with overall findingsState medical cannabis lawsInternational Statistical Classification of DiseasesReceipt of prescription opioidsStatistical Classification of DiseasesElectronic health recordsInternational Classification of DiseasesNon-Hispanic whitesOpioid use disorder diagnosisOpioid use disorder prevalenceInternational Statistical ClassificationDifference-in-differences analysisCannabis lawsUse disorderBurden of opioid use disorderLong-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study
Macmadu A, Li Y, Bhondoekhan F, Chang C, Bahji A, Crystal S, Gordon K, Kerns R, Vickers-Smith R, Edelman E, Marshall B. Long-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study. Addictive Behaviors Reports 2025, 22: 100619. PMID: 40547483, PMCID: PMC12182372, DOI: 10.1016/j.abrep.2025.100619.Peer-Reviewed Original ResearchDepressive symptom severityVeterans Aging Cohort StudySymptom severityOpioid useCohort studySubstance use disordersPrescription opioid useProspective cohort studyOpioid use disorderAging Cohort StudyMental health servicesDose-response patternGeneralized Estimating Equation modelsVeterans Health Administration sitesUse disorderClinical characteristicsProspective cohortBidirectional associationsFollow-upStudy entryOpioidHarm reduction servicesBidirectional relationshipPLHIVAdministration siteUnderstanding the characteristics and comorbidities of primary care patients with risky opioid use: Baseline data from the multi-site “Subthreshold Opioid Use Disorder Prevention” (STOP) Trial
Rostam-Abadi Y, Liebschutz J, Subramaniam G, Stone R, Appleton N, Mazel S, Alexander K, Brill S, Case A, Gelberg L, Gordon A, Hong H, Incze M, Kawasaki S, Kim T, Kline M, Lovejoy T, McCormack J, Zhang S, McNeely J. Understanding the characteristics and comorbidities of primary care patients with risky opioid use: Baseline data from the multi-site “Subthreshold Opioid Use Disorder Prevention” (STOP) Trial. Journal Of General Internal Medicine 2025, 1-10. PMID: 40457116, DOI: 10.1007/s11606-025-09613-4.Peer-Reviewed Original ResearchOpioid use disorderMental health symptomsHigh-risk useOpioid useHealth symptomsConsequences of opioid useSymptoms of opioid use disorderBaseline characteristics of participantsCollaborative care interventionRates of polysubstance usePrimary care patientsPrimary care sitesOpioid use disorder preventionPrimary care settingSelf-reported demographic characteristicsModerate-severe painSevere opioid use disorderCharacteristics of participantsModerate-severe anxietyPrimary careCare interventionsCare sitesCare settingsOpioid medicationsNon-HispanicMedications for opioid use disorder shape immune responses during chronic HIV infection
Collora J, Steinhauser S, Davenport T, Lin D, Eshetu A, Zeidi S, Kim R, Frank C, Kluger Y, Springer S, Ho Y. Medications for opioid use disorder shape immune responses during chronic HIV infection. Cell Reports Medicine 2025, 6: 102159. PMID: 40460829, PMCID: PMC12208330, DOI: 10.1016/j.xcrm.2025.102159.Peer-Reviewed Original ResearchConceptsOpioid use disorderTumor necrosis factorImmune responseHIV infectionAssociated with HIV replicationCytotoxic T cell populationsRisk of opioid use disorderUse disorderPeripheral blood immune cellsI interferonChronic HIV infectionRNA expressionPartial agonist buprenorphineT cell populationsShape immune responsesBlood immune cellsType I interferonImprove immune responsesAgonist buprenorphineAgonist methadoneHIV expressionAntagonist naltrexoneHIV replicationImmune profileImmune cellsAn Evaluation a PrEP-Focused HIV Prevention Intervention Tailored for Individuals with Opioid Use Disorder and Cognitive Dysfunction
Mistler C, Huedo-Medina T, Shrestha R, Gunstad J, Zelenev A, Copenhaver M. An Evaluation a PrEP-Focused HIV Prevention Intervention Tailored for Individuals with Opioid Use Disorder and Cognitive Dysfunction. Neuropsychiatric Disease And Treatment 2025, 21: 1235-1248. PMID: 40584207, PMCID: PMC12205702, DOI: 10.2147/ndt.s490266.Peer-Reviewed Original ResearchHIV risk behaviorsImprove HIV prevention effortsRisk behaviorsHIV prevention outcomesHIV prevention effortsPre-exposure prophylaxisExperimental group participantsCognitive dysfunctionRandomized Controlled TrialsLongitudinal regression analysisPrEP knowledgeIntervention tailoringPrEP outcomesIntervention effectsAdherence skillsPrevention outcomesOpioid use disorderGroup participantsPrevention effortsCompensatory strategiesCondom skillsMOUD patientsOutcome variablesInterventionMOUDThe Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review
Shafie M, Ing K, Rostam‐Abadi Y, Weleff J, Griffin M, Ranganathan M, Aghaei A, Pratt N, Funaro M, Nia A. The Potential Use of Cannabidiol in the Treatment of Opioid Use Disorder: A Systematic Review. Addiction Biology 2025, 30: e70047. PMID: 40415392, PMCID: PMC12104536, DOI: 10.1111/adb.70047.Peer-Reviewed Original ResearchConceptsOpioid use disorderOUD outcomesUse disorderConditioned place preference paradigmPlace preference paradigmReducing withdrawal symptomsPotential of cannabidiolSubstance use disordersEfficacy of cannabidiolTreatment of opioid use disorderPreclinical studiesClinical studiesOpioid use disorder treatmentPreference paradigmAnxiety symptomsWithdrawal symptomsPsychiatric disordersEffective treatment approachTreatment optionsHuman studiesCannabidiolAnimal studiesSystematic reviewShort-term follow-upCravingPharmacological and behavioral pain treatment strategies for patients with opioid use disorder
Ameral V, Hickey T, Reilly E, Patterson J, Sofuoglu M. Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder. Expert Opinion On Pharmacotherapy 2025, 26: 1041-1054. PMID: 40366730, PMCID: PMC12202159, DOI: 10.1080/14656566.2025.2506688.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid use disorderChronic painUse disorderCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsEffective management of painPain treatment strategiesRegister of Controlled TrialsManagement of painCochrane Central RegisterAgonist treatmentPharmacological optionsTreatment strategiesPainOpioidEffective treatmentControlled TrialsBehavioral treatmentTreatmentPatientsDisordersMedical careEffective managementEffective medical careMulti-ancestry genome-wide association meta-analysis of buprenorphine treatment response
Davis C, Khan Y, Crist R, Vickers-Smith R, Hartwell E, Gelernter J, Kampman K, Kember R, Le Moigne A, Laffont C, Kranzler H. Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response. Neuropsychopharmacology 2025, 1-8. PMID: 40328918, DOI: 10.1038/s41386-025-02117-z.Peer-Reviewed Original ResearchGenome-wide association studiesTreatment responseOpioid use disorderGenome-wide significant lociGWAS meta-analysesCross-ancestry meta-analysisClinical characteristicsGenome-wide association meta-analysisGenetic predictors of treatment responseMeta-analysisPresence of chronic painAssociation meta-analysisUse disorderPartial agonist buprenorphinePhenome-wide association analysisTreat opioid use disorderPredictors of treatment responseExtended-release buprenorphineMillion Veteran ProgramSignificant lociLead variantsCross-ancestryAssociation studiesOdds of treatment responseAssociation analysisAssociations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity
SooHoo J, Davis C, Han A, Jinwala Z, Gelernter J, Feinn R, Kranzler H. Associations of Childhood Adversity and Polygenic Scores with Substance Use Initiation and Disorder Severity. Psychological Medicine 2025, 55: e132. PMID: 40314172, PMCID: PMC12094658, DOI: 10.1017/s0033291725001163.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAdverse Childhood ExperiencesAlcoholismBlack or African AmericanFemaleGene-Environment InteractionGenetic Predisposition to DiseaseHumansMaleMarijuana AbuseMiddle AgedMultifactorial InheritanceOpioid-Related DisordersSeverity of Illness IndexSubstance-Related DisordersWhiteYoung AdultConceptsSubstance use disorder severitySubstance use disordersAdverse childhood experiencesGene-by-environment interactionsSubstance Use InitiationPolygenic scoresOpioid use disorderUse disorderEUR individualsAssociated with AUD severityCannabis use disorderAssociated with adverse childhood experiencesSeverity of alcoholismLatent factorsSubstance use disorder riskGene-environment correlationAssociation of childhood adversityAssociation of adverse childhood experiencesAncestry groupsAUD severityDisorder severityChildhood adversityPolygenic riskChildhood experiencesEnvironmental influencesHospital-based Stigma Practices Towards Individuals With Opioid Use Disorder: A Qualitative Study in Austin, Texas Hospital Stigma Practices Impacting Patients With OUD
Christian N, Baysinger A, Bottner R, Cowley C, Nekolaichuk R, Owen P, Smith B, Sue K. Hospital-based Stigma Practices Towards Individuals With Opioid Use Disorder: A Qualitative Study in Austin, Texas Hospital Stigma Practices Impacting Patients With OUD. American Journal Of Medicine Open 2025, 100106. DOI: 10.1016/j.ajmo.2025.100106.Peer-Reviewed Original ResearchOpioid use disorderCare teamCare practicesHospital settingFocus groupsCare experiences of peopleQualitative studyIn-person focus groupsPositive care experiencesHospital-based providersUse disorderHospital-based carePatient-centered practiceExpertise of patientsStigma of patientsExperiences of peopleSemi-structured interviewsInternalized stigmaHealthcare experiencesStigma experiencesCare deliveryCare experiencesReceiving healthcareCategorize themesStigmatizing experiencesInitiating Injectable Buprenorphine in People Hospitalized With Infections
Seval N, Roth P, Frank C, Di Paola A, Litwin A, Vander Wyk B, Neirinckx V, Schlossberg E, Lawson P, Strong M, Schade M, Nunez J, Levin F, Brady K, Nunes E, Springer S. Initiating Injectable Buprenorphine in People Hospitalized With Infections. JAMA Network Open 2025, 8: e2513000. PMID: 40445619, PMCID: PMC12125644, DOI: 10.1001/jamanetworkopen.2025.13000.Peer-Reviewed Original ResearchConceptsLong-acting buprenorphineOpioid use disorderReceipt of MOUDRandomized clinical trialsTAU armIntent-to-treat outcomesClinical trialsModerate to severe opioid use disorderSevere opioid use disorderProportion of patientsMultisite randomized clinical trialHospital settingStatistically significant differenceNursing case management servicesInfectious diseasesTAU groupMedian ageMedication management interventionCase management servicesInjectable buprenorphineHospitalization periodPrimary outcomeBaseline valuesInitiate MOUDMOUD receipt611. Cannabinoid 1 Receptor Availability in Men With Opioid Use Disorder: A Positron Emission Tomography Study
Nia A, Hillmer A, Aghaei A, Pittman B, Huang H, Nabulsi N, D'Souza D. 611. Cannabinoid 1 Receptor Availability in Men With Opioid Use Disorder: A Positron Emission Tomography Study. Biological Psychiatry 2025, 97: s350. DOI: 10.1016/j.biopsych.2025.02.850.Peer-Reviewed Original ResearchMethadone for Opioid Use Disorder in the Fentanyl Era: Navigating Challenges and Evolving Strategies- a Narrative Review
Osagie E, Horton J, Lawrence D, Hermes G, Garcia-Vassallo G. Methadone for Opioid Use Disorder in the Fentanyl Era: Navigating Challenges and Evolving Strategies- a Narrative Review. Current Addiction Reports 2025, 12: 44. DOI: 10.1007/s40429-025-00655-6.Peer-Reviewed Original ResearchOpioid use disorderDosing flexibilityEffective treatmentMethadone treatmentCornerstone of treatmentOpioid use disorder treatmentMethadone initiationMethadone doseDosing daysDosing considerationsDose selectionTreatment outcomesUse disorderWithdrawal managementPresence of fentanylOpioidRate of titrationDoseMethadoneFentanylSummaryThis reviewSynthetic opioidsDrug overdose deathsInitial careClinical decisionsEpidemiology of Opioid Use, Misuse, and Overdoses
Draghmeh K, Gold M, Fuehrlein B. Epidemiology of Opioid Use, Misuse, and Overdoses. Current Addiction Reports 2025, 12: 36. DOI: 10.1007/s40429-025-00649-4.Peer-Reviewed Original ResearchOpioid use disorderEpidemiology of opioid useComplex public health challengesMental health disordersRisk factorsPublic health challengeOpioid useHarm reduction programsSocioeconomic disadvantagePsychosocial interventionsAccess barriersHealth disordersHealth challengesReduction programsOverdose deathsImprove outcomesGenetic predispositionCollaborative effortsPolysubstance useTreatment retentionEpidemiologyInnovative therapiesIncreasing overdose deathsReviewThis reviewLimited accessibility
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply